Status:
TERMINATED
Effects of GLYX-13 on Learning and Memory in Healthy Individuals and Those With Psychiatric Illness
Lead Sponsor:
Northwestern University
Conditions:
Psychiatric Illness
Healthy
Eligibility:
All Genders
18-40 years
Phase:
PHASE2
Brief Summary
The present study proposes to evaluate the potential cognitive enhancing effects of GLYX-13, an NMDAR partial agonist, among a group of healthy adults and those with psychiatric illness on a series of...
Detailed Description
In a single blind randomized parallel group design, we will evaluate the whether a single dose of GLYX-13 vs. placebo increases cognitive performance on tasks of learning, declarative memory, and work...
Eligibility Criteria
Inclusion
- For all Individuals
- Male and female subjects
- Ages 18 - 40 years
- General intellectual abilities falling broadly within the average range (estimated intelligence quotient (IQ) between 80 - 119)
- Sufficient ability to understand study requirements and provide written informed consent
- For Patients
- Diagnosis of Schizophrenia or Schizoaffective Disorder
Exclusion
- For all individuals:
- History of neurologic disorder or systemic medical condition that may interfere with central nervous system function
- History of seizures
- History of heard injury with loss of consciousness or concussion
- Positive screen for drugs of abuse: cocaine, marijuana, phencyclidine, ketamine, opioid, or other agent that is being abused in the opinion of the investigator
- Females who are currently pregnant or plan to become pregnant during the study period
- History of allergy, sensitivity, or intolerance to N-methyl-D-Aspartate receptor (NMDAR) ligands including ketamine, dextromethorphan, memantine, methadone, dextropropoxyphene, or ketobemidone
- History of any ferromagnetic object in the body
- Presence of any medical device or implant for which MRI is contraindicated including cardiac pacemaker, aneurysm clip, cochlear implant, copper intrauterine device (IUD), neurostimulator, or any other device deemed unsafe
- Bullet or shrapnel in body
- Metallic braces or permanent retainer
- Significant claustrophobia
- For Healthy Individuals
- Personal history of any Axis I disorder according to the Structured Clinical Interview for the DSM-5 (SCID-5) criteria
- History of treatment with antidepressant, antipsychotic, stimulant,sedative/ hypnotic, mood stabilizing, or anticholinergic medications or lithium
- History among first-degree family members of any psychotic illness or major mood disorder (e.g., major depressive disorder, recurrent; bipolar I or II disorder)
- For Patients
- Treatment with Clozaril
- Change in medication within 1 month
- Hospitalization within 1 month
Key Trial Info
Start Date :
May 1 2013
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
44 Patients enrolled
Trial Details
Trial ID
NCT01844726
Start Date
May 1 2013
End Date
January 1 2016
Last Update
April 20 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Northwestern University
Chicago, Illinois, United States, 60611